Investigational drug · Phase 2
GAd20-209-FSP
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Tumor, Adult.
Phase 2Last checked: Nov 20, 2026Latest source record: Feb 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "GAd20-209-FSP"
First trial start
2019
Oct 21, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GAd20-209-FSP", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumor, Adult
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "GAd20-209-FSP" as an intervention, largest first.
- Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid TumorsPivotal-lookingActive, not recruiting
Nouscom SRLIndustry
NCT04041310 · 115 participants (planned) · Start Oct 21, 2019 · Primary completion Oct 30, 2026
Drug: GAd-209-FSP low dose; MVA-209-FSP low dose and 5 more · For: Solid Tumor, Adult
Sites: Duarte, California; Irvine, California; Los Angeles, California · 46 sites in all
- A Vaccine (Nous-209) for the Reduction of Colorectal Lesion Size in Patients With Lynch SyndromeNot yet recruiting
National Cancer Institute (NCI)NIH
NCT07937696 · 55 participants (planned) · Start Apr 27, 2027 · Primary completion Nov 30, 2031
Drug: Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP; MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP · For: Colorectal Carcinoma; EPCAM Lynch Syndrome; Lynch Syndrome and 4 more
Sites: Kansas City, Kansas; Boston, Massachusetts; Ann Arbor, Michigan · 5 sites in all
- Cancer Preventive Vaccine Nous-209 for Lynch Syndrome PatientsActive, not recruiting
National Cancer Institute (NCI)NIH
NCT05078866 · 45 participants · Start Nov 10, 2022 · Primary completion Apr 16, 2025
Drug: Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP; MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP · For: Colorectal Carcinoma; Lynch Syndrome
Sites: Duarte, California; Philadelphia, Pennsylvania; Houston, Texas · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Solid Tumor, Adult
- VisugromabCTL-002, Visugromab RDEPhase 36 trials
CatalYm GmbH · Adult Solid Tumor, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Unresectable or Metastatic Hepatocellular Carcinoma
- anzutresgene autoleucelIMA203 Product, IMA203 product- flat dosePhase 32 trials
Immatics US, Inc. · Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
- CRB-701Phase 32 trials
Corbus Pharmaceuticals Inc. · Solid Tumor, Adult, Oropharyngeal Carcinoma (OPC)
- HMPL-453Phase 32 trials
Hutchmed · Advanced Intrahepatic Cholangiocarcinoma, Solid Tumor, Adult, Solid Tumor
- VT3989Phase 32 trials
Vivace Therapeutics, Inc · Pleural Mesothelioma, Mesothelioma, Solid Tumor, Adult
- DabogratinibTYRA-300Phase 24 trials
Tyra Biosciences, Inc · FGFR3 Gene Mutation, FGFR3 Gene Alteration, Achondroplasia
- VS-7375Phase 24 trials
Verastem, Inc. · G12D Mutated KRAS, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
- Tmod CAR T-cell TherapyA2B530, A2B694Phase 23 trials
A2 Biotherapeutics Inc. · Solid Tumor, Adult, Colorectal Cancer, Colorectal Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.